



LENTIFLASH® : A NEW TOOL FOR KNOCK-OUT APPLICATIONS

A. Gene disruption



B. Exon skipping




Duchenne disease model:

- No cure, and current pre-clinical strategies use AAVs (DNA delivery) to deliver gene editing systems
- Restoration of DMD activity using LentiFlash®
- Transient expression of gene editing enzymes minimizes the off-target activity
- Collaboration with Institut Clinique de la Souris (ICS)

A highly promising therapeutic strategy to repair the defective dystrophin gene



LENTIFLASH® : A NEW TOOL FOR KNOCK-IN APPLICATIONS



PRODUCTION OF HIGHLY PURIFIED AND CONCENTRATED LENTIFLASH® PARTICLES

